Widening the field further, Vaxart, Immunovaccine and Mayo Clinic are joining a slew of biotechs and pharmas either exploring or embarking on Zika vaccine development.
South San Francisco-based Vaxart said it has enrolled the first patient in a Phase I trial of the company's oral influenza B vaccine candidate. According to a statement, the vaccine represents the last monovalent component the company needs before it can advance with the development of its quadrivalent influenza vaccine tablet.
While working to catch up with other vaccine developers in the race for a respiratory syncytial virus (RSV) vaccine, San Francisco-based Vaxart this week unveiled data demonstrating its candidate's ability to create a "substantial" immune response in a preclinical challenge model.
As part of its responsibility to prepare for public health threats, the U.S. Department of Health and Human Services' BARDA unit is seeking more effective influenza vaccines to incorporate into its pandemic strategy. Now, it's funding two projects it hopes will help the state of affairs.
Flu shots are a driving sales force for more than a couple vaccine players. But could an oral alternative disrupt the flu vaccine market down the line?
The approval of MedImmune's nasally-administered FluMist in 2003 was the first major advance in the delivery of influenza vaccines since immunization against the flu began in 1945. This week Vaxart raised $20 million to bring about the next step forward--vaccines in tablet form.
Just a few weeks ago Vaxart reported positive data from a Phase I study of its H1N1 flu vaccine in tablet form.
San Francisco-based Vaxart has started dosing patients in its first Phase I trial using its oral vaccine platform. The study uses an H5N1 flu vaccine, but the platform, if effective, could be used
The San Francisco start-up Vaxart has banked a $12.5 million Series B venture round, with the money going to support its work building a portfolio of orally-delivered vaccines. Care Capital of